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The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 
created the largest expansion of benefits in the 40-year history of Medicare. It is also the 
first time in the history of the program that a Medicare benefit will not be available 
through the basic Medicare program but only through enrollment either in a stand-alone 
private drug plan or through a Medicare Advantage managed care plan.  The MMA does 
not allow Medicare to negotiate volume discounts as is done by the Department of 
Veterans Affairs.  The idea behind the law is that choice among seniors and competition 
among the private insurers will lead to lower drug prices.   
 
A few days ago, I received a dreaded phone call from my mother.  No, she wasn’t ill.  
She was calling to ask me to help her enroll in the new Medicare prescription drug plan.  
 
Coincidentally, I was giving a lecture on Medicare to the JMC first year medical students 
the next morning.  I even had a few slides to explain the new Medicare drug plan.  I know 
people have said it is complicated, but it shouldn’t be too hard for me.  I’m computer 
literate; I teach health policy; I’ve been doing health services research for 25 years.  I 
assumed I could just go on-line, help my mother, and get some material for my class at 
the same time.   
 
I signed on to Medicare.gov.  Right there on the home page I saw what I needed.  Just 
click here, it said, and we’ll help you select the correct plan.  Easy.  I entered my 
mother’s zip code and up came this message:  
 
47 Medicare Prescription Drug plans are available in your area 
 
Under this message there was a table summarizing the 47 plans.1  For each of them, it 
told me the monthly premium, annual deductible, cost sharing, coverage in the gap, and 
formulary (percent of drugs covered).   
 
The monthly premiums varied from $4.10 to $85.02.  Both the $4 plan and the $85 plan 
have a $250 annual deductible, no gap coverage, and 25% cost sharing.  Both plans offer 
a choice of convenient local pharmacies in their preferred network.  According to the 
summary table, the formulary for the $4 plan covers 95% of the 200 most commonly 
used drugs by people with Medicare while the $85 plan covers 85%.  I guess that I need 
to dig a little deeper. 
 
The monthly premium seems clear as does the annual deductible, but what do they mean 
by “cost sharing”?  No problem, if I just click on the information icon , a pop-up 
window will explain all.  Here’s the definition of cost sharing:  
 
The copayment and/or coinsurance amount range you will pay for each 
prescription. Plans can make changes in the list of prescription drugs they cover 
and their costs during the year. Call the plan to get all the details of prescription 
drug coverage, including the list of drugs the plan covers, so you understand any 
conditions or limits. 
 
When I clicked on a few of the plan names, I was able to get a bit more information.  The 
copayment and coinsurance seem to differ by “tier.”  Now what does that mean?  I found 
a glossary:  
 
Drug tiers are definable by the plan. The option “tier” was introduced in the PBP 
to allow plans the ability to group different drug types together (i.e., Generic, 
Brand, Preferred Brand). In this regard, tiers could be used to describe drug 
groups that are based on classes of drugs. If the “tier” option is utilized, plans 
should provide further clarification on the drug type(s) covered under the tier in 
the PBP notes section(s). This option was designed to afford users additional 
flexibility in defining the prescription drug benefit. 
 
Searching through a few of the plans, I found that some have fixed dollar copayments 
that differ by tier and some have coinsurance, shown as a percentage, although I’m not 
quite sure what the percentage is based on.  And, if I understand correctly, each plan can 
define its own list of drugs that goes into each tier.  Oops, maybe this isn’t going to be so 
simple. I love my mother, but I’m not sure I really want to call 47 different plans.   
 
Medicare.gov also has a place to enter what drugs you’re taking.  Ah, I thought, maybe 
that will help to narrow things down.  I called my mom and asked her to gather all her 
prescriptions and give me a list.  Her answer was: “I’m not taking any prescription 
drugs.”  That’s great for her, but not much help in picking a drug plan. 
 
Now what?  I work at a medical school so maybe I could call an epidemiologist and ask 
what are the diseases that an 80 year-old woman is most likely to develop, then call a 
pharmacist to ask what are the most appropriate prescription drugs for these diseases, and 
then I would have what I needed to compare the coverage of the different plans.  But that 
wouldn’t work anyway.  Since the plans can change their formulary, their prices, and 
their copayments, I wouldn’t know whether a particular drug would be included by the 
time she needed it and what it would cost. 
 
Apparently, I’m not alone in my confusion.  In a national survey, when asked how well 
they understand the drug benefit, 61% of seniors said “not at all” or “not well”.2  When 
told that most Medicare beneficiaries will have more than 40 plans to choose from 73% 
say that having so many plans “makes it confusing and difficult to pick the best plan.”  
Readers of the Health Policy Newsletter should take note that 75% of seniors expect their 
pharmacists to be very or somewhat knowledgeable about drug plan choices and 65% 
expect the same of their physicians. 
 
So after all of this, what was my advice to my mother?  Don’t do anything – yet.  The 1% 
per month penalty for not enrolling does not start until May 2006.  Maybe some of the 




1. I would have included the table with this article, but at 12 pages it would have 
taken most of this issue of the Health Policy Newsletter. 
2. Source: Kaiser Family Foundation/Harvard School of Public Health Survey.  The 
Medicare Drug Benefit: Beneficiary Perspectives Just Before Implementation 
(conducted October 13-31, 2005) 
 
 
